Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents

E-ISSN： 1365-2710|38|1|41-47

ISSN： 0269-4727

Source： JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol.38, Iss.1, 2013-02, pp. : 41-47

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 269-4727, Iss. 1, 2013-02 ,pp. : 41-47

John Wiley & Sons Inc

Access to resources Recommend Favorite

Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience

Acta Haematologica, Vol. 138, Iss. 1, 2017-07 ,pp. : 55-60

Karger

Access to resources Recommend Favorite

Factors associated with second‐line triplet therapy in routine care in relapsed/refractory multiple myeloma

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 43, Iss. 1, 2018-02 ,pp. : 45-51

John Wiley & Sons Inc

Access to resources Recommend Favorite

Very Low Doses of Thalidomide as Single Agent in Relapsed/Refractory Multiple Myeloma

Acta Haematologica, Vol. 116, Iss. 1, 2006-07 ,pp. : 70-71

Karger

Access to resources Recommend Favorite

Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 2, 2018-02 ,pp. : 179-186

John Wiley & Sons Inc

Access to resources Recommend Favorite